Existing trials of conversational AI have demonstrated improvements in insulin adherence and glycemic control in patients with type 2 diabetes [12], medication adherence in patients with hypertension and diabetes [11], and symptoms of depression and anxiety in college students [13, 14]. This evidence concerns the gene INS and major depressive disorder.